Voya Investment Management LLC Acquires 12,488 Shares of Hologic, Inc. (NASDAQ:HOLX)

Voya Investment Management LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 9.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 138,891 shares of the medical equipment provider’s stock after buying an additional 12,488 shares during the period. Voya Investment Management LLC owned about 0.06% of Hologic worth $10,013,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Benson Investment Management Company Inc. bought a new stake in Hologic in the 4th quarter worth about $4,832,000. Principal Financial Group Inc. grew its holdings in shares of Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after acquiring an additional 1,606 shares in the last quarter. Clean Yield Group grew its holdings in shares of Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after acquiring an additional 7,266 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after acquiring an additional 238,222 shares in the last quarter. Finally, Nordea Investment Management AB grew its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after acquiring an additional 544,889 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.1 %

Shares of HOLX opened at $58.08 on Tuesday. The firm has a market capitalization of $13.03 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1-year low of $55.89 and a 1-year high of $84.67. The company has a 50-day moving average of $60.90 and a 200 day moving average of $69.77.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on HOLX shares. Raymond James reissued an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Morgan Stanley reduced their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. William Blair reissued an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Royal Bank of Canada reduced their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Hologic currently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.